Chugai Pharmaceutical Co., Ltd.
F. Hoffmann-La Roche 2026 Q3 Sales Performance
F. Hoffmann-La Roche announced sales performance for January–September 2026. Roche Holding holds a majority of shares, and the Company's results include figures from the Roche Group. The published materials are posted on the Roche Group website.
Key Figures
- Key Figure 1: Period January 1, 2026 – September 30, 2026
- Key Figure 2: Parent Shareholding Ratio 59.89%
- Key Figure 3: Voting Rights Ratio 61.12%
AI要約
Overview
This report covers F. Hoffmann-La Roche's sales performance for January–September 2026 and notes that Roche Holding holds the majority of Chugai Pharmaceutical Co., Ltd.'s shares. The published materials are available on the Roche Group website, and it should be noted that the Company's January–September results include the Roche Group's figures.
Shareholding and Data Sources
As of June 30, 2026, Roche Holding, the parent company of the Roche Group, holds 59.89% of the Company's issued shares (61.12% voting rights). The published materials are posted on the Roche Group website, and the Company's period results include Roche Group figures.
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
